Who are Kaletra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cresemba, Mycamine, Cancidas, Protonix, Nogitecan, Prevacid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lopinavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Kaletra — Competitive Intelligence Brief

Kaletra (LOPINAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytochrome P450 3A Inhibitor [EPC]. Area: Immunology.

marketed Cytochrome P450 3A Inhibitor [EPC] ATP-binding cassette sub-family G member 2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Kaletra (LOPINAVIR) — Abbvie Deutschland Gmbh Co. Kg. Kaletra blocks the protease enzyme, preventing the HIV virus from replicating.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kaletra TARGET	LOPINAVIR	Abbvie Deutschland Gmbh Co. Kg	marketed	Cytochrome P450 3A Inhibitor [EPC]	ATP-binding cassette sub-family G member 2	2000-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Nogitecan	topotecan	Novartis	marketed	topotecan	ATP-binding cassette sub-family G member 2	1996-01-01
Prevacid	lansoprazole	Generic (originally Takeda)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase	1995-05-10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-04-21 — Prevacid · 11077055 · Formulation · US
2036-04-21 — Prevacid · 11986554 · Formulation · US

Sponsor landscape (Cytochrome P450 3A Inhibitor [EPC] class)

· 2 drugs in this class
Gilead Sciences · 2 drugs in this class
AbbVie · 1 drug in this class
Abbvie Deutschland Gmbh Co. Kg · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kaletra — Competitive Intelligence Brief. https://druglandscape.com/ci/lopinavir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab